Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia
The emergence of the novel coronavirus COVID-19 has raised concerns about the course of this disease in patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). This study aimed to evaluate the incidence, severity, and risk factors for a more severe course of COVID-19 among patients with MS and NMOSD ...
Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network
This study focuses on the description of treatment interruptions and discontinuations in the Big Multiple Sclerosis Data Network registry group. This cohort study, led by Prof. Jan Hillert from Karolinska Institutet, Sweden, pooled data from five clinical registries covering a period of 20 years....
Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system. After the first demyelinating episode, well-established drugs are commonly used in MS patients in the Czech Republic...
What data does the national registry of patients with multiple sclerosis ReMuS offer?
In a review article of the professional journal Neurology for Practice, the expert guarantor of the ReMuS registry focused on the introduction of the ReMuS registry and especially the range of data contained in it. The article also offers insight into the representation of patients in individual MS centres in the Czech Republic, the development of the deployment of highly effective drugs or the very important area of...
Multiple Sclerosis Patient Registry ReMuS - the importance of data in chronic diseases
A new article in the professional journal Remedia provides information on what can be found in the data of the ReMuS multiple sclerosis patient registry and in real clinical practice in the Czech Republic after six years of operation. Since its inception, the records are available...
Initiation of first disease-modifying treatment for multiple sclerosis patients in the Czech republic from 2013 to 2016: Data from the national registry ReMuS
Proper management of multiple sclerosis (MS) treatment requires feedback from clinical practice provided by registries. This article focuses on the introduction of the Czech national multiple sclerosis registry, ReMuS, and examines the availability and use of drugs...
How We Have Progressed Over Five Years of the ReMuS Registry's Existence
In the five years of its existence, the Czech national registry of multiple sclerosis patients, ReMuS, has become an invaluable source of data for clinical practice and research. This article provides an overview of how the registry has evolved since its inception in 2013...
Multiple sclerosis registries in Europe - Updated overview
In 2018, an updated mapping of multiple sclerosis (MS) registries in Europe was conducted, building on a previous survey from 2014. This survey covers 19 registries, mostly from Europe, and provides detailed information on the organisation, data collection methods, quality of control mechanisms and funding ...
A comparison of efficacy of subcutaneous interferon β-1a 44 μg, dimethyl fumarate and fingolimod in the real-life clinical practice – a multicenter observational study
Multiple sclerosis (MS) is a chronic inflammatory demyelinating and neurodegenerative disease affecting the central nervous system. Interferon (IFN) β-1a 44 μg, dimethyl fumarate (DMF), and fingolimod are established drugs for the treatment of relapsing-remitting MS (RR MS). The aim of this project, which involves analysis of data from the ReMuS registry, was to compare ...
ReMuS - The Czech Republic National Multiple Sclerosis Patient Registry
Article doc. Dana Horáková published in Multiple Sclerosis News offers a detailed look at the creation and development of the Czech national registry of multiple sclerosis patients, ReMuS, since its establishment in 2013. The reader will find information about the structure of the registry, the process of data collection,...